Previous 10 | Next 10 |
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations include the first review of primary endpoint results with longer follow-up from the pivot...
Regeneron Pharmaceuticals Inc. (REGN) is expected to report $9.39 for Q3 2023
2023-11-02 13:14:09 ET Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer – President and Chief Executive Officer ...
2023-11-02 06:32:58 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron's hearing loss gene therapy shows positive outcomes in trial For further details see: Regeneron Pharmaceuticals beats Q3 top and ...
TARRYTOWN, N.Y., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced long-term outcomes and new analyses of pivotal clinical data for EYLEA ® HD (aflibercept) Injection 8 mg will be presented at the American Academy of Ophthalmology (AAO)...
2023-11-01 12:43:24 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals, Inc. (RE...
2023-10-29 12:00:27 ET More on PBMs Cigna PBM unit Express Scripts sued for overcharging pharmacies FTC investigating purchasing organizations that work on behalf of PBMs Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices CVS H...
2023-10-29 08:28:00 ET As the calendar turns from October to November, the week promises a flurry of earnings reports from some of the world's most prominent companies. Among the key players stepping into the earnings spotlight will be technology giant Apple ( NASDAQ: AAPL ), semico...
2023-10-27 07:02:48 ET Regeneron ( NASDAQ: REGN ) on Friday announced positive results from a trial investigating its otoferlin gene therapy (DB-OTO) in children with profound genetic hearing loss due to mutations of the otoferlin gene. DB-OTO is an investigational cell-sele...
Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advan...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...